BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251111
DTEND;VALUE=DATE:20251114
DTSTAMP:20260515T035143
CREATED:20250829T114659Z
LAST-MODIFIED:20250829T114659Z
UID:41812-1762819200-1763078399@www.pharmajournalist.com
SUMMARY:7th TIL Therapies Summit
DESCRIPTION:Now in its seventh year\, the TIL Therapies Summit returns as the leading event dedicated to advancing tumor-infiltrating lymphocytes (TIL) therapies. Taking place November 11–13\, 2025\, in Boston (MA)\, this summit unites global experts across biopharma\, academia\, clinical practice\, and manufacturing to accelerate the development and commercialization of next-generation TIL treatments. \nFollowing the first-ever FDA approval of a TIL therapy in the U.S.\, and with regulatory decisions pending in Canada and Europe\, the field is at a pivotal inflection point. The 7th TIL Therapies Summit offers a timely platform to explore how optimized TIL selection\, engineering\, and manufacturing can unlock scalable\, potent treatments for solid tumors beyond melanoma. \nThe program is designed to tackle the most pressing challenges in TIL development\, including: \n\nEngineering TILs for improved persistence\, potency\, and specificity\nManufacturing innovations in closed systems to speed-up turnaround\, and reduce IL-2 dependency\nClinical trial design and patient access strategies\nBiomarker discovery and potency assay development\nReal-world implementation and patient/provider perspectives\n\nWith 28+ expert speakers\, 50+ attendees\, and 8 hours of dedicated networking\, the summit fosters a collaborative environment for sharing cutting-edge science\, operational insights\, and lived experiences. Attendees will hear from leading voices including: \n\nInge Jedema\, Netherlands Cancer Institute\nJingwei Sun\, Grit Biotechnology\nMadan Jagasia\, Obsidian Therapeutics\nMicah Benson\, KSQ Therapeutics\nMichael Lotze\, University of Pittsburgh\nRoda Amaria\, MD Anderson Cancer Center\n\nYou can see who else is speaking in this year’s program: https://ter.li/i4a730 \nWhether you’re preparing for your first clinical trial\, scaling manufacturing\, or navigating regulatory pathways\, this summit delivers actionable insights for every stage of the TIL pipeline. Two new tracks focused on R&D and CMC ensure that both scientific and operational teams gain maximum value. \nUnlike broader cell therapy events\, the TIL Therapies Summit offers a focused\, intimate setting where attendees can engage in meaningful dialogue\, build lasting partnerships\, and stay ahead of the curve in this rapidly evolving space. \nIf you’re committed to transforming the treatment landscape for solid tumors\, the 7th TIL Therapies Summit is your must-attend event for 2025. \nFind out more here: https://ter.li/nfdnks
URL:http://www.pharmajournalist.com/event/7th-til-therapies-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR